Alaunos Therapeutics (TCRT) Income towards Parent Company (2009 - 2026)

Alaunos Therapeutics (TCRT) has 18 years of Income towards Parent Company data on file, last reported at -$1.0 million in Q1 2026.

• Quarterly Income towards Parent Company rose 5.59% year-over-year to -$1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$73.2 million (down 1658.13% YoY) and the FY2025 annual result came in at -$217.8 million, down 4426.37% from the prior year.
• Income towards Parent Company eased to -$1.0 million in Q1 2026, from -$907000.0 in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of -$755000.0 in Q4 2024 to a low of -$70.1 million in Q2 2025.
• A 5-year average of -$9.0 million and a median of -$8.1 million in 2023 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2024 — Income towards Parent Company soared 90.67% — and 2025, when it plunged 5908.06%.
• Tracing TCRT's Income towards Parent Company over 5 years: stood at -$9.4 million in 2022, then rose by 14.12% to -$8.1 million in 2023, then soared by 90.67% to -$755000.0 in 2024, then fell by 20.13% to -$907000.0 in 2025, then retreated by 13.67% to -$1.0 million in 2026.
• The last three Income towards Parent Company figures came in at -$1.0 million (Q1 2026), -$907000.0 (Q4 2025), and -$1.2 million (Q3 2025), per Business Quant data.